BRUSSELS (Reuters) - Belgium-based cancer testing company MDxHealth said on Tuesday it had signed deal with two U.S. health insurers to expand coverage of its ConfirmMDx prostate cancer diagnosis by more than 50 million people.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
MDxHealth said in a statement that it had signed agreements with FedMed, Inc., with 40 million members, and America's Choice Provider Network, Inc., with 11 million members.
The new agreements mean that some 130 million people now have possible access to ConfirmMDx via their health insurance providers.
ConfirmMDx, MDxHealth's first commercial product, aims to distinguish patients with a true-negative biopsy from those who may have undetected cancer.
Currently, repeat biopsies are carried out, many on cancer-free men. ConfirmMDx is designed to help urologists identify truly cancer-free men and allow them to avoid potentially a costly repeat biopsies.
(Reporting By Philip Blenkinsop, editing by Robert-Jan Bartunek)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp